- Home
- SRZN vs CVM Comparison
SRZN vs CVM Comparison
Compare SRZN & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- CVM
- Stock Information
- Founded
- SRZN 2015
- CVM 1983
- Country
- SRZN United States
- CVM United States
- Employees
- SRZN N/A
- CVM N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SRZN Health Care
- CVM Health Care
- Exchange
- SRZN Nasdaq
- CVM Nasdaq
- Market Cap
- SRZN 38.1M
- CVM 40.1M
- IPO Year
- SRZN N/A
- CVM 1987
- Fundamental
- Price
- SRZN $10.57
- CVM $0.72
- Analyst Decision
- SRZN
- CVM
- Analyst Count
- SRZN 0
- CVM 0
- Target Price
- SRZN N/A
- CVM N/A
- AVG Volume (30 Days)
- SRZN 49.1K
- CVM 983.8K
- Earning Date
- SRZN 11-06-2024
- CVM 02-12-2025
- Dividend Yield
- SRZN N/A
- CVM N/A
- EPS Growth
- SRZN N/A
- CVM N/A
- EPS
- SRZN N/A
- CVM N/A
- Revenue
- SRZN $10,000,000.00
- CVM N/A
- Revenue This Year
- SRZN N/A
- CVM N/A
- Revenue Next Year
- SRZN N/A
- CVM $3,412.81
- P/E Ratio
- SRZN N/A
- CVM N/A
- Revenue Growth
- SRZN N/A
- CVM N/A
- 52 Week Low
- SRZN $6.00
- CVM $0.49
- 52 Week High
- SRZN $16.19
- CVM $3.23
- Technical
- Relative Strength Index (RSI)
- SRZN 54.47
- CVM 52.33
- Support Level
- SRZN $9.50
- CVM $0.60
- Resistance Level
- SRZN $11.27
- CVM $1.09
- Average True Range (ATR)
- SRZN 1.10
- CVM 0.12
- MACD
- SRZN 0.01
- CVM 0.02
- Stochastic Oscillator
- SRZN 41.36
- CVM 38.40
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.